Ex vivo magnetofection with magnetic nanoparticles: A novel platform for nonviral tissue engineering

Artificial Organs

Volumn 32, Issue 3, 2008, Pages 195-204

  Yang, Shieh Yueh ^b   Sun, Jui Sheng ^a,c   Liu, Cheng Heng ^b   Tsuang, Yang Hwei ^d   Chen, Li Ting ^e   Hong, Chin Yih ^f   Yang, Hong Chang ^g   Horng, Herng Er ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e Healthbanks Biotechnology Corporation Ltd   (Taiwan)

^f DA YEH UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Ex vivo; Liposome; Magnetic nanoparticles complex; Magnetofection

Indexed keywords

CELL CULTURE; CELL ENGINEERING; EFFICIENCY; GENE EXPRESSION; GENE TRANSFER; LIPOSOMES; MAGNETIC FIELDS; MAGNETITE; MAMMALS; NANOMAGNETICS; NANOPARTICLES; TISSUE ENGINEERING;

DNA EXPRESSIONS; EX-VIVO; EXPRESSION VECTORS; IN-VITRO; MAGNETIC NANOPARTICLE COMPLEX; MAGNETIC-FIELD; MAGNETOFECTION; MAMMALIAN CELLS; NONVIRAL; TISSUES ENGINEERINGS;

DNA;

BETA GALACTOSIDASE; DNA; ENHANCED GREEN FLUORESCENT PROTEIN; LIPOFECTAMINE; MAGNETITE; NANOPARTICLE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; EX VIVO STUDY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; MAGNETIC FIELD; MAGNETISM; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; TISSUE ENGINEERING;

MAMMALIA; MUS;

EID: 40149102045     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2007.00526.x     Document Type: Article

References (51)

1. Felgner PL, Rhodes G. Gene therapeutics. Nature 1991; 349:351–2.
2. Blaese RM, Mullen CA, Ramsey WJ. Strategies for gene therapy. Pathol Biol 1993;41:672–6.
3. Eastman SJ, Siegel C, Tousignant J, Smith AE, Cheng SH, Scheule RK. Biophysical characterization of cationic lipid: DNA complexes. Biochim Biophys Acta 1997;1325:41–62.
4. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996;3:137–44.
5. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998;80:35–47.
6. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999;401:517–8.
7. Felgner PL, Gadak TR, Holm M, et al. Lipofection: a highly efficient, lipidmediated DNA transfection procedure. Proc Natl Acad Sci USA 1987;84:7413–7.
8. Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 1989;337:387–8.
9. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 1989; 86:6077–81.
10. LeVentis R, Silvius JT. Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles. Biochim Biophys Acta 1990;1023:124–32.
11. Nabel EG, Gordon D, Yang ZY, et al. Gene transfer in vivo with DNA–liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther 1992;3:649–56.
12. Caplen NJ, Alton EW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995;1:39–46.
13. Guenzburg WH, Salmons B. Virus vector design in gene therapy. Mol Med Today 1997;1:410–7.
14. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998;16:867–70.
15. Mir LM. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96:4262–7.
16. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999;6:508–14.
17. Kielian T, Hickey WF. Inflammatory thoughts about glioma gene therapy. Nat Med 1999;5:1237–8.
18. Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 1995;92:9742–6.
19. Chu G, Hayakawa H, Berg P. Electroporation for the efficient transfection of mammalian cells with DNA. Nucleic Acids Res 1987;15:1311–26.
20. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5. Virology 1973;52:456– 67.
21. Koropchak JA, Sadain S, Yang X, et al. Nanoparticle detection technology for chemical analysis. Anal Chem 1999;71:386A– 94A.
22. Douglas SJ, Davis SS, Illum L. Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst 1987;3:233–61.
23. 14C-methacrylate) nanoparticle radioactivity after injection in rats and mice. J Pharm Sci 1979;68: 1443–7.
24. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55:329–47.
25. Vijayanathan V, Thomas T, Thomas TJ. DNA nanoparticles and development of DNA delivery vehicles for gene therapy. Biochemistry 2002;41:14085–94.
26. Benns JM, Kim SW. Tailoring new gene delivery designs for specific targets. J Drug Target 2000;8:1–12.
27. Hogemann D, Ntziachristos V, Josephson L, Weissleder R. High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug Chem 2002;13:116– 21.
28. Lanza GM, Yu X, Winter PM, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002;106:2842– 7.
29. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003;63:5838–43.
30. Violante MR. Potential of microparticles for diagnostic tracer imaging. Acta Radiol Suppl 1990;374:153–6.
31. Petersein J, Sainim S, Weissleder R. Liver. II: iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Magn Reson Imaging Clin N Am 1996;4:53–60.
32. Mitchell DG. MR imaging contrast agents—what’s in a name? J Magn Reson Imaging 1997;7:1–4.
33. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J Drug Target 1998;6:167–74.
34. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001;11:2319–31.
35. Jiang WQ, Yang HC, Yang SY, et al. Preparation and properties of superparamagnetic nanoparticles with narrow size distribution and biocompatible. J Magn Magn Mater 2004;283: 210.
36. Tomlinson E, Rolland AP. Controllable gene therapy: pharmaceutics of nonviral gene delivery systems. J Control Release 1996;39:357–72.
37. Wong TK, Neumann E. Electric field mediated gene transfer. Biochem Biophys Res Commun 1982;107:584–7.
38. Sawai K, Meruelo D. Cell-specific transfection of choriocarcinoma cells by using Sindbis virus hCG expressing chimeric vector. Biochem Biophys Res Commun 1998;248:315–23.
39. Berkowitz RD, Ilves H, Plavec I, Veres G. Gene transfer systems derived from Visna virus: analysis of virus production and infectivity. Virology 2001;279:116–29.
40. Muzyczka N, Warrington KH Jr. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 2005;16:408–16.
41. Belletti B, Nicoloso MS, Schiappacassi M, et al. Baldassarre Gp27(kip1) functional regulation in human cancer: a potential target for therapeutic designs. Curr Med Chem 2005;12:1589– 605.
42. Pardridge WM. Gene targeting in vivo with pegylated immunoliposomes. Methods Enzymol 2003;373:507–28.
43. Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002;9:102–9.
44. Huth S, Lausier J, Gersting SW, et al. Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med 2004;6:923–36.
45. Prasher DC. Using GFP to see the light. TIG 1995;11:320–3.
46. Prow T, Smith JN, Grebe R, et al. Construction, gene delivery, and expression of DNA tethered nanoparticles. Mol Vis 2006;12:606–15.
47. Plank C, Anton M, Rudolph C, Rosenecker J, Krotz F. Enhancing and targeting nucleic acid delivery by magnetic force. Expert Opin Biol Ther 2003;3:745–58.
48. Plank C, Scherer F, Schillinger U, Bergemann C, Anton M. Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields. J Liposome Res 2003;13:29–32.
49. Krotz F, Sohn HY, Gloe T, Plank C, Pohl U. Magnetofection potentiates gene delivery to cultured endothelial cells. J Vasc Res 2003;40:425–34.
50. Plank C, Schillinger U, Scherer F, et al. The magnetofection method: using magnetic force to enhance gene delivery. Biol Chem 2003;384:737–47.
51. Krotz F, de Wit C, Sohn HY, et al. Magnetofection—a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 2003;7:700–10.